Role of TGF-β1-activated p38 MAPK in up-regulation of PAI-1 expression by TGF-β1 in human ovarian cancer cells
PAN Xiao-yu1, WANG Yan2, HUANG Gao-xiang2, LU Jian2, QU Shen1
1. Department of Endocrinology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China;
2. Department of Pathophysiology, The Second Military Medical University, Shanghai 200443, China
AIM: To investigate the relationship between up-regulation of plasminogen activator inhibitor-1(PAI-1) expression and activation of p38 mitogen-activated protein kinase(p38 MAPK) and extracellular signal-regulated kinase(ERK) pathways by TGF-β1 in human ovarian cancer cells. METHODS: PAI-1 expression in human ovarian cancer cells treated with TGF-β1(10 μg/L)was assayed by real-time PCR and Western blotting. The activation of p38 MAPK and ERK was determined by Western blotting using phosphorylated p38 MAPK and phosphorylated ERK antibodies. Specific p38 MAPK inhibitor(SB203580) or ERK inhibitor(PD98059) was used to inhibit their activation. RESULTS: TGF-β1 up-regulated the expression of PAI-1, and activated p38 MAPK and ERK pathways in the ovarian cancer cells. Inhibition of p38 MAPK activation by SB203580 resulted in significant inhibition of the mRNA expression of PAI-1 induced by TGF-β1. However, inhibition of ERK activation did not significantly alter TGF-β1-induced increase in PAI-1 mRNA level. CONCLUSION: TGF-β1-activated p38 MAPK pathway contributes to the up-regulation of PAI-1 expression by TGF-β1 in ovarian cancer cells.
潘霄羽, 王燕, 黄高翔, 卢建, 曲伸. TGF-β1激活的p38 MAPK在TGF-β1上调人卵巢癌细胞PAI-1表达中的作用[J]. 中国病理生理杂志, 2015, 31(2): 284-288.
PAN Xiao-yu, WANG Yan, HUANG Gao-xiang, LU Jian, QU Shen. Role of TGF-β1-activated p38 MAPK in up-regulation of PAI-1 expression by TGF-β1 in human ovarian cancer cells. Chin J Pathophysiol, 2015, 31(2): 284-288.
Koensgen D, Mustea A, Denkert C, et al. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer[J]. Anticancer Res, 2006,26(2C):1683-1689.
[5]
Liu YX. Plasminogen activator/plasminogen activator inhibitors in ovarian physiology[J]. Front Biosci, 2004, 9:3356-3373.
[6]
Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease[J].Biochim Biophys Acta,2008, 1782(4):197-228.
[7]
Massagué J.TGFβ in cancer[J]. Cell, 2008, 134(2):215-230.
Zhang YE. Non-Smad pathways in TGF-beta signaling[J]. Cell Res,2009, 19(1):128-139.
[10]
Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene[J]. EMBO J, 1998, 17(11):3091-3100.
[11]
Wong AS, Leung PC.Role of endocrine and growth factors on the ovarian surface epithelium[J]. J Obstet Gynaecol Res, 2007, 33(1):3-16.
[12]
Ma Y, Ryu JS, Dulay A, et al. Regulation of plasminogen activator inhibitor(PAI)-1 expression in a human trophoblast cell line by glucocorticoid(GC) and transforming growth factor(TGF)-beta[J]. Placenta,2002,23(10):727-734.
[13]
Wickert L, Chatain N, Kruschinsky K,et al. Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes[J]. Comp Hepatol, 2007,6:5.
[14]
Chen YX, Wang Y, Fu CC, et al. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells[J]. Endocr Relat Cancer,2010, 17(1):39-50.
[15]
Ohashi K, Yoshimoto T, Kosaka H, et al. Interferon γ and plasminogen activator inhibitor 1 regulate adhesion formation after partial hepatectomy[J]. Br J Surg, 2014, 101(4):398-407.
